Get the Stockscreener App
0.6651
5.91%
0.0371
Moleculin Biotech Inc stock is traded at $0.6651, with a volume of 2.10M.
It is up +5.91% in the last 24 hours and up +104.96% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$0.628
Open:
$0.6
24h Volume:
2.10M
Relative Volume:
0.43
Market Cap:
$20.09M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.0435
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+17.30%
1M Performance:
+104.96%
6M Performance:
-55.95%
1Y Performance:
-70.70%
1-Day Range:
$0.592
$0.6899
1-Week Range:
$0.5327
$0.75
52-Week Range:
$0.25
$3.6499
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.6651 | 18.97M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin receives notice of intent to grant new European patent for Annamycin - MSN
Moleculin Biotech Releases Corporate Presentation Update - TipRanks
Moleculin Biotech Inc. Ranks High in Smart Money TrackerROI Driven Equity Selection With Safety Emphasized - metal.it
What catalysts could drive Moleculin Biotech Inc. stock higher in 2025Post Market Watchlist For Every Investor - jammulinksnews.com
How strong is Moleculin Biotech Inc. company’s balance sheetBreakout Stocks Opportunities Backed By Experts - jammulinksnews.com
What Caused the Sharp Drop in Moleculin Biotech (MBRX.O)? - AInvest
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin - GlobeNewswire
What is Moleculin Biotech Inc. company’s growth strategyFinancial News Tips For Beginners - jammulinksnews.com
Will Moleculin Biotech Inc. Stock Benefit from AI and Green Energy TrendsAccurate Buy Point for Momentum Stocks Detected - metal.it
Moleculin receives European patent notice for cancer drug Annamycin By Investing.com - Investing.com Nigeria
Moleculin receives European patent notice for cancer drug Annamycin - Investing.com
Moleculin Biotech Secures European Patent for Annamycin - TipRanks
Moleculin Biotech, Inc. Receives Notice of Intent to Grant European Patent for Annamycin, Strengthening Market Position in Oncology - Quiver Quantitative
Breakthrough Cancer Drug Patent: Moleculin's Non-Cardiotoxic Treatment Gains EU Protection Until 2040 - Stock Titan
Why Did Moleculin Biotech Inc. (MBRX) Soar 10.08%? - AInvest
Statistical indicators supporting Moleculin Biotech Inc.’s strengthIntraday Trend Analysis for Fast Gains Released - metal.it
Why Did Moleculin Biotech Inc. (MBRX) Soar 11.82%? - AInvest
why MBRX is up afterhours - AInvest
Why Moleculin Biotech Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
What are analysts’ price targets for Moleculin Biotech Inc. in the next 12 monthsConsistently exceptional gains - jammulinksnews.com
When is Moleculin Biotech Inc. stock expected to show significant growthAchieve breakthrough gains with smart trades - jammulinksnews.com
How volatile is Moleculin Biotech Inc. stock compared to the marketCapitalize on market momentum for maximum gains - jammulinksnews.com
What makes Moleculin Biotech Inc. stock price move sharplyGet exclusive market analysis for investors - jammulinksnews.com
Is it the right time to buy Moleculin Biotech Inc. stockExplosive capital gains - jammulinksnews.com
How does Moleculin Biotech Inc. compare to its industry peersOutstanding risk-reward balance - jammulinksnews.com
What are the latest earnings results for Moleculin Biotech Inc.Unlock rapid growth potential in your portfolio - jammulinksnews.com
whats better mbrx or pstv - AInvest
Is Moleculin Biotech Inc. a good long term investmentMassive wealth growth - PrintWeekIndia
How high can Moleculin Biotech Inc. stock price go in 2025High-margin investment plays - jammulinksnews.com
Moleculin Biotech Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
What drives Moleculin Biotech Inc. stock priceUnprecedented market success - PrintWeekIndia
What analysts say about Moleculin Biotech Inc. stockFree Risk Assessment Services - jammulinksnews.com
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan
Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moleculin Biotech Inc Stock (MBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):